POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)
1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		1h0d ANTIBODY FAB
FRAGMENT, HEAVY
CHAIN
(Homo
sapiens)		5 / 12VAL B 163
VAL B 181
SER B 179
ASN B 196
ASN B 155
None
1.44A18.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3g04 HUMAN THYROID
STIMULATING
AUTOANTIBODY M22
HEAVY CHAIN
(Homo
sapiens)		5 / 12VAL B 163
VAL B 182
SER B 180
ASN B 197
ASN B 155
None
1.43A18.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		6 / 12ASP A 110
VAL A 111
SER A 192
PHE A 345
PHE A 346
TYR A 373
ETQ  A1200 (-3.5A)
ETQ  A1200 (-3.4A)
ETQ  A1200 (-3.3A)
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
1.07A56.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12ASP A 110
VAL A 111
SER A 192
SER A 196
PHE A 345
PHE A 346
TYR A 373
ETQ  A1200 (-3.5A)
ETQ  A1200 (-3.4A)
ETQ  A1200 (-3.3A)
ETQ  A1200 ( 4.6A)
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
0.81A56.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12TRP A 109
ASP A 113
VAL A 114
SER A 207
PHE A 289
ASN A 312
TYR A 316
None
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
ERC  A1201 (-2.7A)
ERC  A1201 (-4.5A)
ERC  A1201 (-3.0A)
None
1.19A99.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12TRP A 109
THR A 110
ASP A 113
VAL A 114
SER A 203
PHE A 290
TYR A 316
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
ERC  A1201 (-2.8A)
ERC  A1201 (-4.8A)
None
1.40A99.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		11 / 12TRP A 109
THR A 110
ASP A 113
VAL A 114
VAL A 117
SER A 203
PHE A 289
PHE A 290
ASN A 293
ASN A 312
TYR A 316
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-2.8A)
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
ERC  A1201 (-3.0A)
None
0.67A99.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		11 / 12TRP A 109
THR A 110
ASP A 113
VAL A 114
VAL A 117
SER A 207
PHE A 289
PHE A 290
ASN A 293
ASN A 312
TYR A 316
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-2.7A)
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
ERC  A1201 (-3.0A)
None
0.56A99.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		3ulv FAB12 HEAVY CHAIN
(Homo
sapiens)		5 / 12VAL D 172
VAL D 191
SER D 189
ASN D 206
ASN D 164
None
1.39A17.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		9 / 12TRP A 109
THR A 110
ASP A 113
VAL A 114
SER A 203
PHE A 261
PHE A 262
ASN A 284
TYR A 288
None
CAU  A 500 ( 4.0A)
CAU  A 500 (-3.0A)
CAU  A 500 (-3.5A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.6A)
1.15A57.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		12 / 12TRP A 109
THR A 110
ASP A 113
VAL A 114
VAL A 117
SER A 203
SER A 207
PHE A 261
PHE A 262
ASN A 265
ASN A 284
TYR A 288
None
CAU  A 500 ( 4.0A)
CAU  A 500 (-3.0A)
CAU  A 500 (-3.5A)
CAU  A 500 (-4.2A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.1A)
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-3.4A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.6A)
0.47A57.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4i3r HEAVY CHAIN OF
VRC-PG04 FAB
(Homo
sapiens)		5 / 12VAL H 163
VAL H 182
SER H 180
ASN H 197
ASN H 155
None
1.41A17.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 131
ASP A 135
VAL A 136
PHE A 340
PHE A 341
ASN A 344
TYR A 370
None
ERM  A2001 (-3.2A)
ERM  A2001 (-3.8A)
ERM  A2001 (-4.3A)
None
ERM  A2001 (-4.3A)
ERM  A2001 ( 4.8A)
0.56A31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12TRP A1109
THR A1110
ASP A1113
VAL A1114
SER A1203
PHE A1290
TYR A1316
None
P0G  A1401 ( 3.9A)
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.9A)
None
1.12A49.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		10 / 12TRP A1109
THR A1110
ASP A1113
VAL A1114
VAL A1117
PHE A1289
PHE A1290
ASN A1293
ASN A1312
TYR A1316
None
P0G  A1401 ( 3.9A)
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
None
0.60A49.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		10 / 12TRP A1109
THR A1110
ASP A1113
VAL A1114
VAL A1117
SER A1203
PHE A1289
PHE A1290
ASN A1312
TYR A1316
None
P0G  A1401 ( 3.9A)
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-2.9A)
None
0.70A49.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		9 / 12TRP A1109
THR A1110
ASP A1113
VAL A1114
VAL A1117
SER A1207
PHE A1289
PHE A1290
ASN A1293
None
P0G  A1401 ( 3.9A)
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.8A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
0.83A49.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12VAL A1114
PHE A1289
ASN A1293
ASN A1312
TYR A1316
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.7A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
None
1.30A49.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4py8 ANTIBODY 3.1 HEAVY
CHAIN
(Homo
sapiens)		5 / 12VAL I 168
VAL I 187
SER I 185
ASN I 202
ASN I 160
None
1.40A16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4rnr PGT130 HEAVY CHAIN
(Homo
sapiens)		5 / 12VAL A 163
VAL A 182
SER A 180
ASN A 197
ASN A 155
None
1.43A18.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		4xi5 FAB-94 HEAVY CHAIN
(Homo
sapiens)		5 / 12THR D 168
VAL D 171
VAL D 190
SER D 188
ASN D 205
None
1.20A19.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5cck ANTIBODY 3BC315 FAB
HEAVY CHAIN
(Homo
sapiens)		5 / 12VAL H 163
VAL H 182
SER H 180
ASN H 197
ASN H 155
None
1.40A18.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5dur HEAVY CHAIN OF
ANTIBODY 100F4
(Homo
sapiens)		5 / 12VAL H 171
VAL H 190
SER H 188
ASN H 205
ASN H 163
None
1.38A17.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5i8e VRC34.01 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12VAL A 163
VAL A 182
SER A 180
ASN A 197
ASN A 155
None
1.42A17.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5l0q MAB 8C7 HEAVY CHAIN
(Homo
sapiens)		5 / 12VAL C 170
VAL C 188
SER C 186
ASN C 203
ASN C 162
None
1.43A17.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5nst HEAVY CHAIN OF
ANTIBODY MGD21
(Homo
sapiens)		5 / 12VAL B 300
VAL B 318
SER B 316
ASN B 333
ASN B 292
None
1.41A21.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5t3s FAB 35022 HEAVY
CHAIN
(Homo
sapiens)		5 / 12VAL D 163
VAL D 182
SER D 180
ASN D 197
ASN D 155
None
1.40A18.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Homo
sapiens;
Spodoptera
frugiperda)		6 / 12TRP A 125
ASP A 129
SER A 212
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.3A)
89F  A1201 ( 3.8A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
0.67A11.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Homo
sapiens;
Spodoptera
frugiperda)		6 / 12TRP A 125
ASP A 129
SER A 212
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.3A)
89F  A1201 ( 3.8A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
1.00A11.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5w6g 6649 ANTIBODY HEAVY
CHAIN
(Homo
sapiens)		5 / 12VAL H 175
VAL H 194
SER H 192
ASN H 209
ASN H 167
None
1.42A10.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		6 / 12ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
1.15A27.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		7 / 12ASP A 115
VAL A 116
SER A 196
SER A 200
PHE A 410
PHE A 411
TYR A 438
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
0.84A27.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 130
ASP A 134
SER A 219
ASN A 331
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.2A)
None
None
1.17A9.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 130
ASP A 134
SER A 219
PHE A 328
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.2A)
E2J  A1201 (-4.4A)
None
1.15A9.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 130
ASP A 134
VAL A 135
PHE A 327
PHE A 328
ASN A 331
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.8A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
None
0.63A9.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6cm4 D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12ASP A 114
VAL A 115
PHE A 389
PHE A 390
TYR A 416
8NU  A2001 ( 3.0A)
8NU  A2001 ( 3.5A)
8NU  A2001 ( 4.5A)
8NU  A2001 ( 4.8A)
8NU  A2001 ( 4.9A)
0.49A11.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6cm4 D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12ASP A 114
VAL A 115
SER A 197
PHE A 389
PHE A 390
8NU  A2001 ( 3.0A)
8NU  A2001 ( 3.5A)
8NU  A2001 ( 3.6A)
8NU  A2001 ( 4.5A)
8NU  A2001 ( 4.8A)
0.84A11.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		6 / 12TRP S 125
ASP S 129
SER S 212
PHE S 330
PHE S 331
TYR S 359
None
EP5  S 401 (-3.3A)
EP5  S 401 (-3.3A)
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
0.64A9.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		6 / 12TRP S 125
ASP S 129
SER S 212
PHE S 330
PHE S 331
TYR S 359
None
EP5  S 401 (-3.3A)
EP5  S 401 (-3.3A)
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
1.00A9.93